| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-117 |
Sentence |
denotes |
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): |
| TextSentencer_T2 |
118-144 |
Sentence |
denotes |
A molecular docking study. |
| TextSentencer_T3 |
145-150 |
Sentence |
denotes |
AIMS: |
| TextSentencer_T4 |
151-309 |
Sentence |
denotes |
A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. |
| TextSentencer_T5 |
310-437 |
Sentence |
denotes |
The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. |
| TextSentencer_T6 |
438-706 |
Sentence |
denotes |
There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. |
| TextSentencer_T7 |
707-805 |
Sentence |
denotes |
Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries. |
| TextSentencer_T8 |
806-819 |
Sentence |
denotes |
MAIN METHODS: |
| TextSentencer_T9 |
820-1067 |
Sentence |
denotes |
In this study, the RNA-dependent RNA polymerase (RdRp) of the newly emerged coronavirus is modeled, validated, and then targeted using different anti-polymerase drugs currently on the market that have been approved for use against various viruses. |
| TextSentencer_T10 |
1068-1081 |
Sentence |
denotes |
KEY FINDINGS: |
| TextSentencer_T11 |
1082-1256 |
Sentence |
denotes |
The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. |
| TextSentencer_T12 |
1257-1444 |
Sentence |
denotes |
In addition, the results suggest guanosine derivative (IDX-184), Setrobuvir, and YAK as top seeds for antiviral treatments with high potential to fight the SARS-CoV-2 strain specifically. |
| TextSentencer_T13 |
1445-1458 |
Sentence |
denotes |
SIGNIFICANCE: |
| TextSentencer_T14 |
1459-1601 |
Sentence |
denotes |
The availability of FDA-approved anti-RdRp drugs can help treat patients and reduce the danger of the mysterious new viral infection COVID-19. |
| TextSentencer_T15 |
1602-1724 |
Sentence |
denotes |
The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. |
| TextSentencer_T16 |
1725-1848 |
Sentence |
denotes |
No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. |
